Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3898117 | 1.00 | DRD2 (0.46) | DRD2BTKJAK1KMT2AL3MBTL1 | |
| SCHEMBL3897829 | 1.00 | DRD2 (0.46) | DRD2BTKJAK1KMT2AL3MBTL1 | |
| SCHEMBL3911519 | 1.00 | DRD2 (0.46) | DRD2BTKJAK1KMT2AL3MBTL1 | |
| SCHEMBL3910610 | 0.81 | DRD2 (0.46) | DRD2BTKJAK1KMT2AL3MBTL1 | |
| SCHEMBL3901028 | 0.81 | DRD2 (0.48) | DRD2BTKJAK1KMT2AL3MBTL1 | |
| SCHEMBL3899426 | 0.81 | DRD2 (0.46) | DRD2BTKJAK1KMT2AL3MBTL1 | |
| SCHEMBL5262280 | 0.81 | DRD2 (0.49) | DRD2BTKJAK1KMT2AL3MBTL1 | |
| SCHEMBL3900553 | 0.81 | DRD2 (0.49) | DRD2BTKJAK1KMT2AL3MBTL1 | |
| SCHEMBL3904876 | 0.79 | DRD2 (0.46) | DRD2BTKJAK1KMT2AL3MBTL1 | |
| SCHEMBL3911664 | 0.77 | NFKB1 (0.40) | DRD2BTKJAK1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893103-B2 | Dipeptidyl peptidase IV (DPP-IV); industrial scale process of making antidiabetics such as (2S,4S)-1-{2-[(3SR,1RS)-3-(1H-1,2,4-Triazol-1-ylmethyl)cyclopentylamino]acetyl}-4-fluoro-pyrrolidine-2-carbonitrile starting from ethyl glyoxalate and 3-(1H-1,2,4-triazol-1-ylmethyl)cyclopententylamine for example | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2011-02-22 | — | — | US | disclosed |
| US-7538128-B2 | Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-05-26 | — | — | US | disclosed |
| US-7524844-B2 | Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-04-28 | — | — | US | disclosed |
| US-20080076818-A1 | NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-03-27 | — | — | US | disclosed |
| US-20070238728-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-10-11 | — | — | US | disclosed |
| US-20070232608-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-10-04 | — | — | US | disclosed |
| US-7205323-B2 | Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-04-17 | — | — | US | disclosed |
| US-20060142585-A1 | Novel dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACETUCALS, S.A. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142585-A1 | Novel dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | DPP4, DPP3, DPP7 | DRD2 2892/4885BTK 3741/4885JAK1 1825/4885 |
| US-20080076818-A1 | NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS | DPP4, DPP7, DPP3 | DRD2 2943/4885BTK 3806/4885JAK1 1204/4885 |
| US-20070232608-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | DPP4, DPP3, DPP7 | DRD2 3063/4885BTK 3630/4885JAK1 1866/4885 |
| US-20070238728-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | DPP4, DPP3, DPP7 | DRD2 3063/4885BTK 3630/4885JAK1 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.